Navigation Links
Dyadic International Reports Q2 2014 Financial Results
Date:8/14/2014

JUPITER, Fla., Aug. 14, 2014 /PRNewswire/ -- Dyadic International, Inc. ("Dyadic") (OTCQX: DYAI), a global biotechnology company whose patented and proprietary technologies are used to develop, manufacture and sell enzymes and other proteins for the bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme industries, today announced financial results for the second quarter ended June 30, 2014.

Logo- http://photos.prnewswire.com/prnh/20110621/CL06708LOGO

Chief Executive Officer, Mark Emalfarb, stated, "The past quarter continued to be an extremely exciting time at dyadic from both a business and technology perspective. Our business performance has been strong with year-over-year product related revenue growth of 28% and R&D revenue growth of 56% through the first six months of 2014. The margins in our enzyme product sales have improved by 18% during the first half of this year.  In the second generation biofuel space, we are looking forward to and expect to start receiving milestone and royalty revenue in the second half of 2014 as Abengoa reported that they have already begun producing their enzymes and is shortly expected to start up their Hugoton Cellulosic Ethanol plant.  Additionally, we recently signed a collaboration agreement with CIMV, a leading biofuel pretreatment technology company.  We have, or expect to have, R&D project extensions with several of our major partners including Sanofi, BASF and our confidential animal feed licensee. We are continuing our commitment to building a world-class team by hiring a new CFO and new member Board of Directors this past quarter.  We are also continuing our commitment to shareholders to become a fully SEC reporting company, and expect that our Form 10 registration documents will be filed today after close of business"

Q2 2014 Financial ResultsRevenue

Net product related revenue for the six months increased 28% to $4.9 million from $3.8 million for the same period a year ago.  The relatively high growth rate for the period was driven by increased sales in nearly all of our market segments, with the animal food and nutrition (24% growth), starch and alcohol (65% growth) and brewing (63% growth) markets showing the largest increase for the six months.

License fee revenue for the six months decreased $5.0 million as no license fee contracts were signed in the first half of 2014.  In Q2 2013, we entered into a license agreement with BASF which had a $5.0 million upfront license fee.

Research and development revenue for the six months increased 56% to $1.1 million compared to $725,000 for 2013.  The increase was due in part to several projects meeting certain milestone targets and objectives sooner than originally anticipated.  Additionally, a number of projects accounted for on the completed contract basis, met their technological milestones and deliverables.

Total revenue for the six months decreased $3.6 million to $6.0 million compared to $9.6 million for the same period last year.  The decrease in license fee revenue of $5.0 million previously discussed was offset by increases in product related revenue of $1.1 million and research and development revenue of $405,000 for the six months ended June 30, 2014.

Gross Profit

Gross profit for the six months decreased to $1.9 million compared to $5.7 million for the same period a year ago.  The decrease came primarily from the decrease in license fee revenue of $5.0 million and the related margin that a license transaction would recognize.  Excluding the effects of the decrease in license fee revenues, gross profit for the six months ended June 30th increased from 14% in 2013 to 32% for the six months ended June 30, 2014.  The increase was due to a combination of higher fermentation and recovery yields for our enzyme products, lower raw material costs, and meeting certain contractual milestones sooner on a number of our research and development projects.

Operating Expenses

General and Administrative Expenses

General and administrative expenses were $3.6 million for the six months ended June 30, 2014 as compared to $2.4 million for the six months ended June 30, 2013, an increase of 51%.  A significant portion of the increase in G&A expenses were attributable to the $1.1 million in continued and ongoing legal and expert work in connection with our lawsuit against our former outside legal counsel. 

Sales and Marketing

Sales and Marketing expenses for the six months ended June 30, 2014 rose 39% to $583,000.  The increase was due in part to the addition of a new animal feed enzyme salesman in June 2013, and additional compensation and travel costs which were incurred in support of new more aggressive sales initiatives.  Additionally, new sales resources were brought in late in the second quarter of 2014. 

Research and Development

Research and Development expenses for the six month period ending June 30, 2014 was up 15% to $655,000.  The increase was originally expected to be higher as resources were being allocated to internal research projects, however, a number of externally funded research projects required additional resources for certain periods of time, which increased our research and development revenue.

As a result of the above discussion, overall operating expenses for the six months ended June 30, 2014 increased 42% to $4.9 million compared to $3.4 million for the same period last year.

Net Income (Loss)

Net loss for the six months was $3.2 million, or ($0.10) per basic diluted share, compared to a net income of $1.9 million, or $0.06 per basic and $0.05 per diluted share, for the same period a year ago.  Exclusive of litigation related legal fees, the net loss for the six months ended June 30, 2014 would have been $2.2 million, or ($0.06) per basic and fully diluted share, as compared to net income of $2.3 million, or $0.07 per basic and fully diluted share, for the six months ended June 30, 2013.

Financial Position and Cash Flow Analysis

At June 30, 2014, cash and cash equivalents were $4.3 million compared to $8.9 million at December 31, 2013.  During the six months ended June 30, 2014, the Company used approximately $4.6 million in cash and cash equivalents versus generating $3.1 million for the same period in 2013.  A significant portion of the $4.6 million reduction in cash and cash equivalents for the six months ended June 30, 2014 was to fund the litigation against outside legal counsel and restock our inventory levels to ensure we had adequate inventory levels on hand to service our customers. 

Capital expenditures for the six months ended June 30, 2014 were approximately $147,000 and cash generated from the exercise of warrants and stock options was $40,000 through the repayment of stock subscriptions receivable.

Cash Flow From Operating Activities

As reflected in our condensed consolidated financial statements, we incurred a loss of approximately $3.2 million and a profit of $1.9 million for the six months ended June 30, 2014 and 2013, respectively.  Net cash used in operating activities was approximately $4.5 million for the six months ended June 30, 2014.  Net cash provided by operating activities for the six months ended June 30, 2013 was $3.1 million. 

From Investing Activities

For the six months ended June 30, 2014, our net cash used in investing activities was approximately $164,000 as compared to approximately $132,000 for the six months ended June 30, 2013. This increase of approximately $32,000 is mainly due to the increase in our capital expenditures at our research center in The Netherlands in support of our new product development initiatives.  The expansion of the lab was completed in January 2014.

From Financing Activities

For the six months ended June 30, 2014, net cash provided by financing activities was $40,000. This amount was received as a repayment of a stock subscription receivable under our 2013 Employee Loan Program (the "Loan Program"), in connection with their exercise of stock options to purchase 250,000 shares of common stock. 

Stockholder's Equity at June 30, 2014 and 2013

Our history of operating losses has resulted in an accumulated deficit of approximately $81.8 million and total negative stockholders' equity of approximately $245,000 as of June 30, 2014.  Total stockholders' equity was approximately $2.7 million as of December 31, 2013. 

The financial information contained in this earnings press release should be read in conjunction with the financial statements and related footnotes which have been posted on the OTC marketplace website at www.otcmarkets.com/stock/DYAI/filings and on Dyadic's website at www.dyadic.com/investorinfo/financials/.

Conference CallDyadic's 2014 second quarter financial results conference call is scheduled for 5:00 p.m. Eastern Standard Time on Thursday, August 14, 2014. The conference call may be accessed by dialing 888-596-2611 (from the United States or Canada) or 913-981-5559 (from other countries) five to ten minutes prior to start time and providing the passcode 1132588. A replay of the conference call will be available on Dyadic's website (www.dyadic.com) shortly after the live event.

About DyadicDyadic International, Inc. is a global biotechnology company that uses its patented and proprietary technologies to conduct research, development and commercial activities for the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme industries. Dyadic utilizes an integrated technology platform based on its patented and proprietary C1 microorganism, which enables the development and large scale manufacture of low cost enzymes and other proteins for diverse market opportunities. The C1 platform technology can also be used to screen for the discovery of novel genes. In addition to the sale of proprietary enzyme products, Dyadic actively pursues licensing arrangements and other commercial opportunities to leverage the value of these technologies by providing its partners and collaborators with the benefits of manufacturing and/or utilizing the enzymes and other proteins which these technologies help produce. Please visit Dyadic's website at www.dyadic.com. Dyadic trades on the OTCQX tier of the OTC marketplace. Investors can find real-time quotes, market information and financial reports for Dyadic on the OTC marketplace website at www.otcmarkets.com/stock/DYAI/quote.

Cautionary Note Regarding Forward-Looking StatementsCertain statements contained in this earnings press release are "forward-looking statements" within the meaning of the federal securities laws. Statements about our beliefs and expectations regarding our technology platform, our licensing strategy, our ability to create higher margin products, expected litigation costs, our ability to continue past success and the enormous potential and value of C1 as well as  statements containing the words "may," "could," "would," "should," "believe," "expect," "anticipate," "plan," "estimate," "target," "project," "intend" and similar expressions may constitute forward-looking statements. These forward-looking statements involve risks, uncertainties and other factors that could cause Dyadic's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements in this earnings press release. Investors are urged to consider these factors carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such forward-looking statements. Any forward-looking statements speak only as of the date of this earnings press release and, except as required by law, Dyadic expressly disclaims any intent or obligation to update or revise any forward-looking statements to reflect actual results, any changes in expectations or any change in events. If Dyadic does update one or more forward-looking statements, no inference should be drawn that it will make additional updates with respect to those or other forward-looking statements. Factors that could cause results to differ materially include, but are not limited to: (1) general economic conditions, including the recent conditions in the global markets; (2) Dyadic's ability to retain and attract employees; (3) competitive pressures and reliance on key customers and collaborators; (4) Dyadic's research and development efforts, (5) the outcome of the current litigation by Dyadic against its former counsel and (6) other factors discussed in Dyadic's publicly available filings, including the risk factors included in Dyadic's Annual Report filed with the OTC Markets Group on March 31, 2014.

 DYADIC INTERNATIONAL, INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Six Months Ended June 30,  Three Months Ended June 30, 2014201320142013Revenue: (Unaudited)  (Unaudited)  (Unaudited)  (Unaudited) Product Related Revenue, Net

$

4,916,724

$

3,837,358

$

2,457,564

$

1,742,286License Fee Revenue-5,000,000-5,000,000Research and Development Revenue1,129,991725,248604,119338,512Total Revenue6,046,7159,562,6063,061,6837,080,798Cost of Goods Sold:4,137,3043,898,0022,158,3391,936,610Gross Profit1,909,4115,664,604903,3445,144,188Expenses:General and Administrative3,628,5872,405,7391,732,8801,147,375Sales and Marketing 582,970419,612341,550215,682Research and Development 655,171569,494321,987279,910Foreign Currency Exchange Loss (Gain), Net(12,000)33,05030,852(27,243)Total Expenses4,854,7283,427,8952,427,2691,615,724Income (Loss) from Operations(2,945,317)2,236,709(1,523,925)3,528,464Other Income (Expense) Interest Income16,5333,0166,8821,738Interest Expense(338,822)(339,641)(169,979)(169,924)Gain on Sale of Fixed Assets19,755-8,155-Total Other Income (Expense)(302,534)(336,625)(154,942)(168,186)Income (Loss) Before Provision for Income Taxes(3,247,851)1,900,084(1,678,867)3,360,278Provision for Income Taxes-(38,000)-(38,000)Net Income (Loss)

$

(3,247,851)

$

1,862,084

$

(1,678,867)

$

3,322,278Net Income (Loss) per Common Share  Basic

$

(0.10)

$

0.06

$

(0.05)

$

0.10  Diluted

$

(0.10)

$

0.05

$

(0.05)

$

0.10Weighted Average Common Shares Used in Calculating  Net Income (Loss) Per Share:  Basic34,036,29532,135,52534,043,74532,232,003  Diluted34,036,29534,175,46734,043,74534,136,986 DYADIC INTERNATIONAL, INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED BALANCE SHEETSJune 30, 2014December 31, 2013ASSETS(Unaudited)Current Assets:Cash and Cash Equivalents$

4,300,494$

8,892,396Restricted Cash171,329200,378Accounts Receivable, Net1,394,6511,677,338License Fee Receivable-110,693Inventory, Net3,830,8072,800,090Prepaid Expenses and Other Current Assets296,981171,601Total Current Assets9,994,26213,852,496Fixed Assets, Net557,009504,781Intangible Assets, Net581,896566,867Other Assets35,22216,173$

11,168,389$

14,940,317LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)Current Liabilities:Accounts Payable$

2,051,353$

2,573,106Accrued Expenses439,921469,681Accrued Interest Payable169,736171,601Note Payable to Stockholder1,424,941-Deferred Research and Development Obligation508,948914,769Convertible Subordinated Debt6,818,000-Total Current Liabilities11,412,8994,129,157Note Payable to Stockholder-1,424,941Convertible Subordinated Debt-6,818,00011,412,89912,372,098COMMITMENTS AND CONTINGENCIESStockholders' Equity (Deficit):Preferred Stock, $.0001 Par Value:Authorized Shares – 5,000,000; None Issued and Outstanding--Common Stock, $.001 par value,Authorized Shares – 100,000,000; Issued and Outstanding – 34,043,745 and 34,028,245, Respectively34,04434,028Additional Paid-in Capital81,585,62181,209,585Stock Subscriptions Receivable(145,963)(182,838)Stock to be Issued49,96427,769Accumulated Deficit(81,768,176)(78,520,325)Total Stockholders' Equity (Deficit)(244,510)2,568,219$

11,168,389$

14,940,317 

 DYADIC INTERNATIONAL, INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Six Months Ended June 30, 20142013 (Unaudited)  (Unaudited) Operating Activities Net Income (Loss) 

$

(3,247,851)$

1,862,084 Adjustments to Reconcile Net Income (Loss) to Net Cash Provided By (Used In) Operating Activities:  Depreciation and Amortization of Fixed Assets 114,98896,171 Amortization of Intangible and Other Assets 30,34424,762 Gain on Sale of Fixed Assets (19,755)- Reserve (Recovery) of Doubtful Accounts 30,072(315,567) Increase (Decrease) in Inventory Reserve (52,000)224,000 Share-Based Compensation Expense 395,122318,597 Changes in Operating Assets and Liabilities:  Accounts Receivable 252,61514,865 License Fee Receivable 110,693208,750 Inventory (978,717)370,366 Prepaid Expenses and Other Current Assets (125,380)45,518 Other Assets (19,049)- Accounts Payable (521,753)89,522 Accrued Expenses (29,760)27,476 Accrued Interest Payable (1,865)167,991 Income Taxes Payable -38,000 Deferred Research and Development Obligation (405,821)(105,767) Net Cash Provided By (Used In) Operating Activities (4,468,117)3,066,768 Investing Activities  Purchases of Fixed Assets (167,216)(100,077) Proceeds from Sale of Fixed Assets 19,755- Cost of Patents (45,373)(34,924) Restricted Cash29,0493,024 Net Cash (Used In) Investing Activities (163,785)(131,977) Financing Activities  Proceeds from Stock Warrant Exercises -64,803 Proceeds from Stock Option Exercises -58,500 Proceeds from Repayment of Stock Subscriptions Receivable 40,000- Net Cash Provided by Financing Activities 40,000123,303 Net Increase (Decrease) in Cash and Cash Equivalents (4,591,902)3,058,094 Cash and Cash Equivalents at Beginning of Period 8,892,3963,990,062 Cash and Cash Equivalents at End of Period 

$

4,300,494$

7,048,156 Supplemental Cash Flow Information:  Cash Paid for Interest 

$

340,687$

169,745 Non-Cash Item:  Conversion of Convertible Debt into Shares of Common Stock 

$

-$

182,000 Non-Cash Advances to Employees for Stock Warrant and Stock Option Exercises 

$

3,125$

131,980 


'/>"/>
SOURCE Dyadic International, Inc.
Copyright©2014 PR Newswire.
All rights reserved


Related biology technology :

1. Dyadic And CIMV Enter Into Collaboration To Commercialize Second Generation Biofuel Technology
2. Thomas Dubinski joins Dyadic as Chief Financial Officer
3. Dyadic International To Present At Two Major Conferences In December 2013
4. Dyadic International Reports Third Quarter 2013 Financial Results
5. Dyadic International To Announce Third Quarter 2013 Financial Results And Host Conference Call On Thursday, November 14, 2013
6. Dyadic International Reports Second Quarter 2013 Financial Results
7. Dyadic International To Present At World Biotechnology Congress 2013 And BIO World Congress On Industrial Biotech
8. Dyadic International Reports First Quarter 2013 Financial Results
9. Dyadic International To Announce First Quarter 2013 Financial Results And Host Conference Call On Wednesday, May 15, 2013
10. Danai Brooks Joins Dyadic International as Chief Operating Officer
11. Dyadic International To Speak At Advanced Biofuels Leadership Conference Panel Discussion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... ... 2016 , ... PharmApprove announced today the hiring ... for Rare Disorders (NORD). Dorman will lead PharmApprove efforts to work with patients, ... drug regulatory review process. , “Adding Diane Dorman is just the latest in ...
(Date:2/9/2016)... Three-Year Initiative Supports Next Generation of Medical Geneticists and  ... Experiences SHPG ) ... of children born with rare diseases, as well as the future ... a new initiative designed to positively affect the lives of children ... disease care. --> To mark the company,s founding 30 ...
(Date:2/8/2016)... 8, 2016 Should antibiotic bone cement products ... to prevent infection after standard total hip or knee ... ECRI Institute have been fielding a lot lately. ... Bottom Line?" --> "Antibiotic Bone ... --> While there isn,t a simple ...
(Date:2/8/2016)... ... February 08, 2016 , ... Thomas J. Todorow has joined ... President for Corporate Services and the Chief Financial Officer at The Children’s Hospital ... Treasury, Managed Care Contracting, Supply Chain, and Investments. , Prior to joining CHOP ...
Breaking Biology Technology:
(Date:1/20/2016)... Jan. 20, 2016   MedNet Solutions , an ... spectrum of clinical research, is pleased to announce the ... achievements are the result of the company,s laser focus ... eClinical , it,s comprehensive, easy-to-use and highly affordable ... --> Key MedNet growth achievements in 2015 include: ...
(Date:1/18/2016)... , Jan. 18, 2016  Extenua Inc., ... that simplifies the use and access of ubiquitous ... go-to-market partnership with American Cyber.  ... extensive experience leading transformational C4ISR and Cyber initiatives ... integrating the latest proven technology solutions," said ...
(Date:1/13/2016)... ALBANY, New York , January 13, 2016 /PRNewswire/ ... Transparency Market Research has published a new market report ... Share, Growth, Trends, and Forecast, 2015 - 2023. According to ... mn in 2014 and is anticipated to reach US$1,625.8 ... from 2015 to 2023. In terms of volume, the ...
Breaking Biology News(10 mins):